Structure Therapeutics Inc GPCR

$17.12 -0.24 (-1.38%)

Valuation

Market cap
1,272,445,000
Revenue TTM
$0
Net income TTM
$-141,200,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
690,800
Avg volume
1,232,066
Day's range
$16.88 – $17.95
Shares out
70,030,000
Stochastic %K
0%
Beta
-1.12
Analysts
Strong Buy
Price target
$105.87

Price

Company profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweig...

Show more

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 457 1978
Website
https://structuretx.com
Address
601 Gateway Boulevard, Suite 900, South San Francisco, United States

Latest news

Stocktwits

BeyondtheCouch Nov 19, 11:05 PM
$GPCR possibly close to my entry point now
0 replies
mendryl2 Nov 19, 3:34 PM
$GPCR crazy price
1 replies
blocktrade Nov 18, 8:53 PM
$VKTX $GPCR 🐶💩
0 replies
TradeSun Nov 18, 8:26 PM
$XBI I think we’re getting closer to a buying window for small- and mid-cap biotech. Pull up the five-year charts on $ALT, $GPCR, $AUTL, and $CABA. Several of these names are trading near the bottom of their five-year ranges. September 21 is where the selloff starts to stand out to me. Treasury yields pushed higher in the days that followed. The 10-year hit its highest level since 2007, the 30-year reached levels last seen in 2004, and the 2-year climbed as well. I think this sector is due for a rebound at some point. Take a look at the charts.
5 replies
Theflash88 Nov 18, 7:06 PM
$GPCR Tax loss taking effect.
0 replies
SendingTheWolf Nov 18, 4:06 PM
$VKTX $$GPCR $RYTM Are we going to get some M&A in this sector or is everyone willing to cede the entire obesity market to Lilly?
2 replies
JonathanV Nov 17, 11:06 PM
$GPCR this price is unfathomable
2 replies
buylowhope Nov 17, 5:35 PM
$GPCR Morgan must be buying like crazy with a 117 price target.
1 replies